Pharma has so far been exempted from Trump's tariff blitz, which imposed a flat rate of 10% on imports from 5th April and much higher levels on countries deemed to have the greatest trade surplus with ...

For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than addressing the root cause of disease. However, cell and gene therapy (CGT) is ...

Medical affairs teams produce evidence-based, non-promotional scientific content for healthcare professionals (HCPs), while marketing teams develop engaging materials on overlapping topics such as ...

The SCOPE study of iSCIB1+, an off-the-shelf DNA plasmid vaccine that will be tested in combination with checkpoint ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

For example, if they are trained on data that reflects existing disparities in treatment or demographics, the AI could perpetuate these inequalities, leading to poorer patient outcomes. To guard ...

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

At Reuters Pharma USA last month, Editor in Chief Jonah Comstock caught up with John Androsavich, general manager of Gingko ...

Chris Molloy, CEO of the Medicines Discovery Catapult, one of the latest members of the UK’s Catapult network, explains why SMEs are set to power future medicines development. We are familiar ...

In the pharmaceutical and cosmetic sectors, innovation often stems from discovering new applications for known compounds. In these situations, an innovator cannot patent the compound itself ...

Coined by industry as the only meeting of its kind, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical, translational, and clinical bottlenecks ...